What is Zacks Research’s Forecast for HALO FY2026 Earnings?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research lifted their FY2026 earnings estimates for Halozyme Therapeutics in a research note issued on Thursday, August 27th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $8.24 per share for the year, up from their previous forecast of $7.56. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $7.75 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2026 earnings at $2.53 EPS, Q1 2027 earnings at $1.78 EPS, Q4 2027 earnings at $3.03 EPS, FY2027 earnings at $9.01 EPS, Q1 2028 earnings at $2.05 EPS, Q2 2028 earnings at $2.71 EPS and FY2028 earnings at $10.06 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS.

HALO has been the subject of a number of other research reports. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday. Morgan Stanley dropped their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $83.00 to $110.00 in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Stock Up 1.8%

Halozyme Therapeutics stock opened at $109.66 on Thursday. The stock has a market cap of $12.45 billion, a P/E ratio of 32.73, a P/E/G ratio of 0.43 and a beta of 0.88. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $109.76. The company’s 50-day moving average price is $89.29 and its two-hundred day moving average price is $75.36.

Institutional Trading of Halozyme Therapeutics

Large investors have recently bought and sold shares of the business. Measured Wealth Private Client Group LLC lifted its holdings in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the last quarter. MidFirst Bank acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $28,000. Finally, Quantbot Technologies LP bought a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $30,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. This trade represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 32,478 shares of company stock worth $3,076,604. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Analysts raised near- and medium-term forecasts: Zacks Research increased its FY2026 EPS estimate to $8.24 from $7.56, above the current consensus of $7.75. Estimates were also raised for Q4 2026, Q1 2027, FY2027, Q1 2028 and Q2 2028. These revisions suggest improving expectations for Halozyme’s royalty and drug-delivery business.
• Positive Sentiment: Buy rating reaffirmed: HC Wainwright maintained a “buy” rating and a $115 price target, implying additional upside from the stock’s recent trading level. The endorsement provides further support for the bullish outlook.
• Positive Sentiment: Momentum and fundamentals remain strong: Halozyme recently reported quarterly EPS of $2.28, well ahead of the $1.79 analyst consensus, while revenue rose 47.7% year over year to $481 million. The company’s FY2026 guidance calls for EPS of $8.65 to $9.00. Halozyme Therapeutics Hits New 1-Year High
• Neutral Sentiment: Investor conferences scheduled: Chief Executive Officer Helen Torley and Chief Financial Officer Darren Snellgrove will participate in upcoming investor conferences and meetings. The events could provide updates on ENHANZE and Halozyme’s expanded drug-delivery portfolio, but no new financial information was announced. Halozyme to Participate at Upcoming Investor Conferences
• Negative Sentiment: One longer-term estimate was trimmed: Zacks lowered its FY2028 EPS forecast to $10.06 from $10.21. However, the reduction was modest and was partly offset by higher estimates for several intervening quarters.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.